DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

Xinyan Liu, Jinming Fu, Haoran Bi, Anqi Ge, Tingting Xia, Yupeng Liu, Hongru Sun, Dapeng Li and Yashuang Zhao *

Abstract

Background: As biomarkers, DNA methylation is used to detect colorectal cancer (CRC) and make assessment of CRC prognosis. The published findings showed the association between the methylation of SFRP1, SFRP2, and WIF1, located in the Wnt signaling pathway, and the prognosis of CRC were not consistent. Our study aimed to explore the potential possibility of SFRP1, SFRP2, and WIF1 concomitant promoter methylation as prognostic biomarkers of postoperative CRC patients.

Methods: A total of 307 sporadic postoperative CRC patients were followed up, we detected SFRP1, SFRP2, and WIF1 methylation obtained from tumor tissues and adjacent non-tumor tissues respectively on the basis of methylation-sensitive high resolution melting analysis. Univariate and multivariate Cox regressions were carried out so as to assess the potential possibility of SFRP1, SFRP2, and WIF1 promoter methylation as predictors of prognosis. Confounders in our study were controlled by Propensity Score (PS) analysis.

Results: The SFRP1, SFRP2, and WIF1 methylation levels in tumor tissues were significantly higher than that in adjacent non-tumor tissues (P < 0.001). SFRP2 hypermethylation was significantly associated with a favorable clinical outcome at the hazard ratio (HR) of 0.343 [95% confidence intervals (CI): 0.164–0.718, P = 0.005] and 0.410 (95% CI: 0.200–0.842, P = 0.015) in multivariate Cox regression and PS analysis, respectively. Co-hypermethylation of SFRP1 and SFRP2 was significantly associated with a favorable clinical outcome at the HR of 0.333 (95% CI: 0.159–0.694, P = 0.003) and 0.398 (95% CI: 0.192–0.821, P = 0.013) in multivariate Cox regression and PS analysis, respectively. Co-hypermethylation of SFRP1, SFRP2 and WIF1 was significantly associated with a favorable clinical outcome at the HR of 0.326 (95% CI: 0.117–0.908, P = 0.032) and 0.401 (95% CI: 0.146–1.106, P = 0.077) in multivariate Cox regression and PS analysis, respectively.

Conclusions: SFRP1, SFRP2, and WIF1 were frequently hypermethylated in CRC tumor tissues. It was apparent that the promoter hypermethylation of SFRP2 and co-hypermethylation of SFRP1 and SFRP2 might be considered as independent prognostic predictors for survival advantage of postoperative CRC patients.

Keywords: Colorectal cancer, Methylation, Prognosis, Wnt signaling pathway

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Colorectal cancer (CRC) has a high estimated death of 881,000 and ranks second in terms of mortality worldwide in 2018 [1]. The global burden of CRC is estimated to reach 1,100,000 cancer deaths by 2030 [2]. The 5-year relative survival rate for CRC patients is about 64.9%, which has remained less than 50% in low-income countries [3, 4]. Though removing the primary tumor by surgery is considered as the most common treatment for CRC patients, approximately 50% of postoperative patients will suffer a tumor recurrence over in the first three years [4]. So far, pathological staging and specific histological features have been seen as the most accurate prognostic predictors for postoperative CRC patients. However, patients with similar characteristics experience different prognosis. Therefore, more effective prognostic biomarkers might be a key to reduce deaths owing to CRC.

DNA methylation, as the most popular epigenetic alteration, could regulate gene expression through the modification of chromatin complexes and the recruitment of methyl-CpG domain-binding proteins around CpG islands [5]. Sufficiently powered clinical studies have revealed the potential feasibility of using specific methylated DNA signatures as CRC prognostic biomarkers in tumor tissues [6]. Studies have proposed that the hypermethylation of CDKN2A promoter and hypomethylation of LINE-1 were independently associated with shorter survival in CRC patients [7, 8].

CRC results from an accumulation of genetic and epigenetic changes in intestinal epithelial cells. Nevertheless, the activation of the Wnt signaling pathway plays an essential role in the emergence of CRC. The DNA hypermethylation of SFRP1, SFRP2, and WIF1, which is located in the upstream of the canonical Wnt signaling pathway, leads to the downregulation of the gene expression, inhibition of gene function, activation of Wnt pathway and promotion of CRC [9, 10]. Also, the DNA hypermethylation of these genes could be used as a biomarker for detecting CRC [11–13]. SFRP1 and SFRP2 included in the SFRPs family, and WIF1 are frequently hypermethylated in cell lines and tissues of CRC [9, 14]. This hypermethylation associated with a lack of expression could be restored by 5-aza-2′-deoxycytidine treatment [15–17]. Rawson et al. discovered that SFRP1 methylation was not associated with recurrence-free survival in two large populations of CRC patients [18]. However, Kumar et al. found that promoter hypermethylation of SFRP1 might be related to the poor prognosis of CRC [19]. Tang et al. revealed that promoter methylation of SFRP2 in CRC tissues could be used as an independent prognostic factor for overall survival [20]. Samaei et al. reported that the overall survival rate of CRC patients with unmethylated WIF1 was significantly higher than that with WIF1 methylation by univariate analysis, whereas SFRP2 methylation was not associated with overall survival rate [21]. The relationship between promoter methylation of SFRP1, SFRP2, and WIF1 and the prognosis of CRC patients is unclear. Therefore, we would study and evaluate promoter methylation of SFRP1, SFRP2, and WIF1 of the Wnt signaling pathway in CRC tissues. Furthermore, we also investigated the association between the methylation of these genes and the prognosis of postoperative CRC patients.

Methods
Study subjects and data collection
Three hundred and seven sporadic primary CRC patients confirmed by pathological diagnosis were collected from a follow-up study of 453 patients. These patients underwent surgical resection in the Third Affiliated Hospital of Harbin Medical University from November 2004 to July 2005 and from May 2007 to January 2008. None of the patients had any other history of cancer or received pre-operative radiotherapy or chemotherapy. Clinical data of age, gender, tumor markers, clinic pathologic characteristics, and clinical information about disease and treatment were collected from the medical record registration system. All participants provided written informed consent. The Research Ethics Committee of Harbin Medical University approved this study.

The last follow-up date for this study was March 15, 2014 (which lasted 109 months). The time from patient’s surgery to death of various reasons or the last follow-up visit was defined as the overall survival (OS) time.

DNA extraction and sodium bisulfate modification
Genomic DNA from patient’s tumor tissue and adjacent non-tumor tissue specimens was extracted by the classic phenol-chloroform method and then was stored at −80°C.

We used a commercially available DNA modification kit (EpiTect Bisulfite Kit®, Qiagen, Hilden, Germany) to bisulfate the genomic DNA and stored them at −20°C. All processing steps were performed according to the instructions provided by the manufacturer.

Methylation analysis of SFRP1, SFRP2, and WIF1
We detected and analyzed methylation of SFRP1, SFRP2, and WIF1 using methylation-sensitive high resolution melting (MS-HRM) by LightCycler 480 (Roche Applied Science, Mannheim, Germany) with gene scanning software, as previously published [22].

All the target amplicons in our study were located in the promoter region of the three genes. The primers of SFRP1 and SFRP2 were designed as reported previously [23], and other primers were
designated through Primer 5.0 software. All primers and conditions for the three genes in MS-HRM analysis were shown in Additional file 1: Table S1.

The whole reaction volume of PCR mixture was 5 μL consisting of 2.5 μL of 1 X Light-Cycler 480 High Resolution Melting Master Mix (Roche), 0.6 μL MgCl2 (3 mM), 0.125 μL of each forward and reverse primer (10 μM), 1.15 μL of polymerase chain reaction (PCR)-grade water and 0.5 μL of bisulfite-treated DNA respectively. The cycling protocol started with one cycle at 95°C for 10 min, accompanied with 50 cycles at 95°C for 10 s, a touchdown for 30 s (0.4°C/step), 72°C for 20 s, and a HRM step at 95°C for 1 min, 40°C for 1 min, and 70°C for 5 s. The melting step strictly followed a continuous acquisition between 70°C and 93°C at 40 acquisitions per 1°C.

A series of methylation standards were constructed, which included 100, 50, 35, 20, 10, 5 and 0% methylated DNA. In the context of universal unmethylated DNA, the series of standards were constructed by serially diluting the methylated control DNA into the unmethylated control according to mass concentration. A water-blank control was included in each batch and all samples were conducted in duplicate to ensure the repeatability of the experiment.

Validation analysis with TCGA data
We further utilized The Cancer Genome Atlas (TCGA) datasets to validate the relationship between SFRP1, SFRP2, and WIF1 methylation in tumor tissues and CRC patient prognosis. The DNA methylation detected by Illumina Human Methylation 450 in colon cancer and rectal cancer were downloaded and merged from UCSC Xena (https://xena.ucsc.edu/). The cg04255616 probe and cg25185173 probe were located in the target amplicon of SFRP1 and SFRP2 in our study, respectively, which were used to analyze DNA methylation and patient prognosis. However, none of the probes of WIF1 deriving from the TCGA were located in the target amplicon of our study. Therefore, we used the average methylation values of all probes to replace the WIF1 methylation level, and then analyzed DNA methylation and CRC patient prognosis (Additional file 2: Figure S1).

Statistical analysis
The missing values of our research were filled by the multiple imputation method. We used the cut-off values of methylation, which were determined by the receiver operator characteristic (ROC) curve to clearly distinguish the tumor tissues from the adjacent non-tumor tissues and the hypomethylation from hypermethylation in tumor tissues. The χ2 test was used to assess the association between the methylation of SFRP1, SFRP2, and WIF1 and clinic pathologic characteristics. We analyzed the survival rates using the life table method and compared the differences among the groups by log-rank test. The effects of SFRP1, SFRP2, and WIF1 methylation on OS were estimated using univariate and multivariate Cox regression. Additionally, GraphPad Prism 7.0 was used to construct the survival curve. The statistical analyses were performed using SPSS version 23.0 software. Two-sided P values less than 0.05 were considered as significant.

Firstly, as SFRP1 and SFRP2 are members of the SFRPs family, we combined the two genes methylation as co-methylation-2 group to explore the association between gene methylation and CRC prognosis. Patients with promoter hypermethylation of SFRP1 and SFRP2 were classified as co-methylation-2H group, while others were as co-methylation-2L group. Secondly, we combined the methylation of SFRP1, SFRP2, and WIF1 co-methylation-3 group to explore the relationship between co-methylation and patient prognosis, since they regulate the Wnt signaling pathway to promote CRC development. On the other hand, patients with promoter hypermethylation of SFRP1, SFRP2, and WIF1 were defined as co-methylation-3H group while others were as co-methylation-3L group.

The propensity score (PS) method was used to balance the characteristics differences between the two methylation groups. Principally, a multivariate logistic regression model was established to estimate the PS, including the variables related to both gene methylation and CRC prognosis, or the CRC prognosis only. The PS based on it was defined as PS-1 [24]. In terms of the comprehensive literature, we set up PS-2 to evaluate all variables relevant to the prognosis of CRC patients for sensitivity analyses. The model incorporated the following factors such as age, gender, CEA [25], CA19–9 [26], multiple polyps [27], tumor location [28], TNM staging, pathological classification [29], histologic classification [30], differentiation degree, postoperative chemotherapy and postoperative radiotherapy.

Meanwhile, we also performed subgroup analyses based on age (< 45 years-old; ≥ 45 years-old), gender (male; female), tumor location (colon; rectum), TNM staging (I-II; III-IV) and postoperative chemotherapy as sensitivity analyses.

Results
SFRP1, SFRP2, and WIF1 methylation in tumor and adjacent non-tumor tissues
We had detected the methylation of SFRP1, SFRP2, and WIF1 for 187 adjacent non-tumor tissue specimens and 307 primary tumor tissue specimens. The SFRP1, SFRP2, and WIF1 methylation levels in tumor tissues were significantly higher than that in adjacent non-tumor tissues (Mann-Whitney U test, P < 0.001) (Additional file 3: Table S2).
The cut-off values of SFRP1, SFRP2, and WIF1 methylation were 10.0, 5.0 and 20.0%, respectively, which had high predictive ability to distinguish tumor tissues from adjacent non-tumor tissues. As shown in Fig 1, the area under curve (AUC) of SFRP1, SFRP2 and WIF1 were 0.916 (95% CI: 0.888–0.939), 0.814 (95% CI: 0.777–0.848) and 0.806 (95% CI: 0.768–0.840), respectively (Table 1). In adjacent non-tumor tissues, the number of patients with SFRP1, SFRP2, and WIF1 methylation levels exceeding the cut-off value were 5 (2.7%), 7 (3.7%) and 41 (21.9%), respectively.

For further survival analysis, the cut-off values of SFRP1, SFRP2, and WIF1 methylation for distinguishing the survival status accounted for 10.0, 50.0, and 50.0% in tumor tissues. According to the cut-off values, the patients were categorized into hypomethylation group and hypermethylation group.

The association between SFRP1, SFRP2, and WIF1 methylation in tumor tissues and clinic pathologic characteristics of CRC patients
The median age of diagnosis for 307 CRC patients was 58 years old (varying from 25 to 80 years old) while the male-to-female ratio was 1.42. Promoter methylation of SFRP1 was associated with age (P = 0.040), lymph nodes involved (P = 0.036), histologic classification (P = 0.044) and differentiation degree (P = 0.011). SFRP2 promoter methylation was associated with TNM staging (P = 0.042), and the proportion of patients with hypermethylation was higher in the I-II stage. WIF1 promoter methylation was associated with pathological classification (P = 0.023) (Table 2).

The association between SFRP1, SFRP2, and WIF1 methylation in tumor tissues and CRC prognosis
One hundred and nine months’ follow-up revealed 41.4% (127/307) of the CRC patients died while 46.9% (144/307) alive with the follow-up mean of 76.90 months and 73-month median of OS time for all patients (Additional file 4: Table S3).

The 5-year and 8-year survival rates of patients with SFRP1 hypermethylation were 68.3 and 56.2%, respectively, which were significantly higher than that of patients with hypomethylation (47.2 and 25.8%, respectively). The 3-year, 5-year and 8-year survival rate of patients with SFRP2 hypermethylation were 92.8, 90.4, and 82.2%, respectively, which were significantly higher than that of patients with hypomethylation (72.0, 60.3 and 45.5%, respectively) (Table 3).

In the multivariate Cox regression, the results showed that CA19–9, TNM staging, differentiation degree and postoperative radiotherapy were independent prognostic biomarkers for CRC patients (Additional file 5: Table S4).

SFRP2 hypermethylation was significantly associated with a favorable clinical outcome with the HR of 0.343 (95% CI: 0.164–0.718, P = 0.005), 0.410 (95% CI: 0.200–0.842, P = 0.015) and 0.455 (95% CI: 0.219–0.944, P = 0.034) in multivariate Cox regression, PS-1 and PS-2 analysis, respectively (Table 4, Fig. 2). Co-hypermethylation of SFRP1 and SFRP2 was significantly associated with a
favorable clinical outcome with the HR of 0.333 (95% CI: 0.159–0.694, *P* = 0.003), 0.398 (95% CI: 0.192–0.821, *P* = 0.013) and 0.442 (95% CI: 0.212–0.923, *P* = 0.030) in multivariate Cox regression, PS-1 and PS-2 analysis, respectively (Table 4, Fig. 5). Co-hypermethylation of SFRP1, SFRP2, and WIF1 was significantly associated with a favorable clinical outcome with the HR of 0.326 (95% CI: 0.117–0.908, *P* = 0.032) in multivariate Cox regression, however, the results showed that this co-methylation was not associated with prognosis in PS-1 analysis, with HR of 0.401 (95% CI: 0.146–1.06, *P* = 0.077) (Table 4).

For colon cancer patients, SFRP2 hypermethylation patients and co-hypermethylation of SFRP1 and SFRP2 patients had a significantly favorable outcome through multivariate Cox regression, PS-1 and PS-2 analysis. For male CRC patients, SFRP2 hypermethylation patients and co-hypermethylation of SFRP1 and SFRP2 patients had a considerably positive outcome only in multivariate Cox regression. In CRC patients with TNM staging III/IV, SFRP2 hypermethylation patients had a significantly definite outcome with the HR of 0.280 (95% CI: 0.097–0.809, *P* = 0.019) in multivariate Cox regression. Co-hypermethylation of SFRP1 and SFRP2 patients had significantly favorable outcome with the HR of 0.263 (95% CI: 0.092–0.751, *P* = 0.013) and 0.352 (95% CI: 0.127–0.970, *P* = 0.044) in multivariate Cox regression and PS-1, respectively. For postoperative chemotherapy patients, co-hypermethylation of SFRP1 and SFRP2 patients had a relatively optimistic outcome in multivariate Cox regression (Table 5).

**Validation results with TCGA data**

The TCGA dataset included a total of 399 patients, of which 88 died. The follow-up period ranged from 6 to 4502 days. The median age of diagnosis was 66 years old (ranging from 31 to 90 years old), and the male-to-female ratio was 1.17.

The cg04255616 probe (SFRP1), cg25185173 probe (SFRP2), and WIF1 methylation levels of adjacent non-tumor tissues were significantly lower than those of tumor tissues (Mann-Whitney U test, *P* < 0.001). There was no direct relevance between the methylation of cg04255616 probe (SFRP1), cg25185173 probe (SFRP2) and the prognosis of CRC patients in multivariate Cox regression. WIF1 hypomethylation was significantly associated with survival advantage in CRC patients, with the HR of 2.022 (95% CI: 1.309–3.124, *P* = 0.002) in multivariate Cox regression. In addition, the co-methylation of SFRP1 and SFRP2 and the co-methylation of SFRP1, SFRP2, and WIF1 were not significantly associated with the prognosis of CRC (Additional file 6: Table S5).

**Discussion**

The Wnt signaling pathway plays an essential role in the development and progression of CRC. Promoter hypermethylation of SFRP1, SFRP2, and WIF1 involved in CRC has been described as negative regulators of the canonical Wnt pathway. Evidence has shown that DNA methylation could be developed as prognostic biomarkers in CRC [6]. However, the implications of SFRP1, SFRP2, and WIF1 promoter methylation on the prognosis of CRC patients were not clear. As far as we know, it is the first study on investigating the association between SFRP1, SFRP2, and WIF1 concomitant promoter methylation and prognosis of CRC patients.

MS-HRM is a simple, reliable and high sensitive technique, which can even assess individual CpG site and detect low-abundance (as low as 0.1–1%) methylation [22]. Liu et al. [31] had indicated significant consistency of gene methylation between the detection of pyrosequencing methods and MS-HRM in our laboratory.

In this study, we found that the promoter methylation level of SFRP1, SFRP2, and WIF1 was enormously higher in tumor tissues than that in adjacent non-tumor tissues. The findings were similar to those of previously published studies [17, 32, 33]. The sensitivity and specificity of SFRP1 were 82.0 and 97.3% respectively for methylation in tumor tissues and adjacent non-tumor tissues in our study. Zhang et al. showed that the sensitivity and specificity of SFRP1 were 89 and 86% respectively for the methylation detected in stool DNA [34]. Due to different methylation detection methods and test samples, it might explain why results difference between us and other researchers exist. The improved specificity would increase the positive predictive value in judging CRC tumor tissue and adjacent non-tumor tissue.

SFRP1 hypermethylation tended to occur frequently to tumors of patients with ≥60 years old, no lymph nodes involved, adenocarcinoma and moderate or well differentiation degree in the current study. Hu et al. also revealed that the percentage of methylated reference was higher in patients at more than 60 and no lymph nodes.

**Table 1** The ROC analysis of gene methylation in tumor and adjacent non-tumor tissues

| Gene   | Cut-off value | Sensitivity | Specificity | AUC (95%CI) | *P* value |
|--------|--------------|-------------|-------------|-------------|-----------|
| SFRP1  | 10.0%        | 82.0%       | 97.3%       | 0.916 (0.888–0.939) | < 0.0001 |
| SFRP2  | 5.0%         | 69.6%       | 96.3%       | 0.814 (0.777–0.848) | < 0.0001 |
| WIF1   | 20.0%        | 77.5%       | 78.1%       | 0.806 (0.768–0.840) | < 0.0001 |

*Area Under Curve (95% Confidence Interval)*
Table 2 Association of promoter methylation with clinic pathologic characteristics of CRC patients \( (N = 307) \)

| Characteristics          | Total N | SFRP1 N (%) | SFRP2 N (%) | WIF1 N (%) |
|--------------------------|---------|-------------|-------------|------------|
|                          | N       | Hypo-M     | Hyper-M     | P value    | Hypo-M     | Hyper-M     | P value    |
| All cases                | 307     | 55 (17.9)  | 252 (82.1)  | 264 (86.0) | 43 (14.0)  | 224 (73.3)  | 83 (26.7)  |
| Age                      |         |             |             |            |             |             |            |
| < 45 years-old           | 33      | 7 (12.7)   | 26 (10.3)   | 26 (9.8)   | 7 (16.3)   | 27 (12.1)   | 6 (7.2)    |
| 45~60 years-old          | 132     | 31 (56.4)  | 101 (40.1)  | 113 (42.8) | 19 (44.2)  | 96 (42.9)   | 36 (43.4)  |
| ≥ 60 years-old           | 142     | 17 (30.9)  | 125 (49.6)  | 125 (47.4) | 17 (39.5)  | 101 (45.0)  | 41 (49.4)  |
| Gender                   |         |             |             |            |             |             |            |
| Male                     | 180     | 33 (60.0)  | 147 (79.3)  | 155 (58.7) | 25 (58.1)  | 136 (60.7)  | 44 (53.0)  |
| Female                   | 127     | 22 (40.0)  | 105 (41.7)  | 109 (41.4) | 18 (41.9)  | 88 (39.3)   | 39 (47.0)  |
| CEA                      |         |             |             |            |             |             |            |
| < 5 ng/mL                | 130     | 23 (41.8)  | 107 (42.5)  | 108 (40.9) | 22 (51.2)  | 94 (42.0)   | 36 (43.4)  |
| ≥ 5 ng/mL                | 177     | 32 (58.2)  | 145 (57.5)  | 156 (59.1) | 21 (48.8)  | 130 (58.0)  | 47 (56.6)  |
| CA19-9                   |         |             |             |            |             |             |            |
| < 37 U/mL                | 232     | 37 (67.3)  | 195 (77.4)  | 196 (74.2) | 36 (83.7)  | 166 (74.1)  | 66 (79.5)  |
| ≥ 37 U/mL                | 75      | 18 (32.7)  | 57 (22.6)   | 68 (25.8)  | 7 (16.3)   | 58 (25.9)   | 17 (20.5)  |
| Multiple polyps          |         |             |             |            |             |             |            |
| No                       | 220     | 41 (74.5)  | 179 (71.0)  | 185 (70.1) | 35 (81.4)  | 155 (69.2)  | 65 (78.3)  |
| Yes                      | 87      | 14 (25.5)  | 73 (29.0)   | 79 (29.9)  | 8 (18.6)   | 69 (30.8)   | 18 (21.7)  |
| Tumor location           |         |             |             |            |             |             |            |
| Colon                    | 115     | 18 (32.7)  | 97 (38.5)   | 96 (36.4)  | 19 (44.2)  | 83 (37.1)   | 32 (38.6)  |
| Rectum                   | 192     | 37 (67.3)  | 155 (61.5)  | 168 (63.6) | 24 (55.8)  | 141 (62.9)  | 51 (61.4)  |
| TNM Staging              |         |             |             |            |             |             |            |
| I- II                    | 163     | 24 (43.6)  | 139 (55.2)  | 134 (50.8) | 29 (67.4)  | 115 (51.3)  | 48 (57.8)  |
| III-IV                   | 144     | 31 (56.4)  | 113 (44.8)  | 130 (49.2) | 14 (32.6)  | 109 (48.7)  | 35 (42.2)  |
| Tumor invasion           |         |             |             |            |             |             |            |
| T1- T3                   | 151     | 24 (42.9)  | 127 (70.4)  | 125 (47.3) | 26 (60.5)  | 105 (46.9)  | 46 (55.4)  |
| T4                       | 156     | 31 (56.4)  | 125 (49.6)  | 139 (52.7) | 17 (39.5)  | 119 (53.1)  | 37 (44.6)  |
| Lymph nodes involved     |         |             |             |            |             |             |            |
| N0                       | 173     | 24 (43.6)  | 149 (59.1)  | 143 (54.2) | 30 (69.8)  | 123 (54.9)  | 50 (60.2)  |
| N1- N2                   | 134     | 31 (56.4)  | 103 (40.9)  | 121 (45.8) | 13 (30.2)  | 101 (45.1)  | 33 (39.8)  |
| Metastasis status        |         |             |             |            |             |             |            |
| M0                       | 284     | 53 (96.4)  | 231 (91.7)  | 242 (91.7) | 42 (97.7)  | 209 (93.3)  | 75 (90.4)  |
| M1                       | 23      | 2 (3.6)    | 21 (8.3)    | 22 (8.3)   | 1 (2.3)    | 15 (6.7)    | 8 (9.6)    |
| Pathological classification |       |             |             |            |             |             |            |
| Prominence               | 199     | 31 (56.4)  | 168 (66.7)  | 168 (63.6) | 31 (72.1)  | 135 (60.3)  | 64 (77.1)  |
| Ulceration               | 86      | 16 (29.1)  | 70 (27.8)   | 78 (29.5)  | 8 (18.6)   | 71 (31.7)   | 15 (18.1)  |
| Others                   | 22      | 8 (14.5)   | 14 (5.5)    | 18 (6.9)   | 4 (9.3)    | 18 (8.0)    | 4 (4.8)    |
| Histologic classification |         |             |             |            |             |             |            |
| Adenocarcinoma           | 235     | 35 (63.6)  | 200 (79.4)  | 203 (76.9) | 32 (74.4)  | 176 (78.6)  | 59 (71.1)  |
| Mucinous adenocarcinoma  | 68      | 19 (34.5)  | 49 (19.4)   | 59 (22.3)  | 9 (20.9)   | 45 (20.1)   | 23 (27.7)  |
| Others                   | 4       | 1 (1.9)    | 3 (1.2)     | 2 (0.8)    | 2 (4.7)    | 3 (1.3)     | 1 (1.2)    |
metastasis. However, there is no radical difference in methylation between the different patients [9]. Galamb et al. also proposed that hypermethylation of the SFRP1 promoter was associated with aging [35]. Kumar et al. reported that SFRP1 promoter methylation was associated with lymph nodes metastasis [19]. Bartak discovered that the SFRP1 methylation was not connected with lymph node metastasis [36]. We found that SFRP2 methylation was associated with TNM staging while WIF1 methylation with pathological classification. Other researches did not report similar results [21, 36, 37]. The different findings above might be determined by different methods of methylation detections, sample sizes of the study cohort or compositions of the sample.

We found that SFRP2 methylation had a more significant impact on prognosis, with the HR of 0.343 (0.164–0.718) in multivariate Cox regression. In addition, patients with hypermethylation of both SFRP1 and SFRP2 and patients with hypermethylation of SFRP1, SFRP2, and WIF1 were at lower risk of death than that with non-all hypermethylation. However, the relationship between co-methylation-3 (SFRP1, SFRP2, and WIF1) and the prognosis was inconsistent with multivariate Cox regression and PS-1, with the HR of 0.401 (0.146–1.106) in PS-1. Therefore, further research is needed to validate this result.

Combining these results, we believed that the co-methylation of multiple genes was better in evaluating the prognosis of patients compared with single genes.

PS is considered as a powerful method for balancing numbers of confounding factors in observational studies [38]. After PS adjustment, the relationships between SFRP2 methylation, co-methylation-2 and the CRC prognosis were slightly increased compared with that based on the crude HR, which also suggested the reliability of the results. The PS-1 model focused on age, gender, CEA, CA19–9, TNM staging, pathological

| Table 2 Association of promoter methylation with clinic pathologic characteristics of CRC patients (N = 307) (Continued) |
|---|
| Characteristics | Total | SFRP1 N (%) | | SFRP2 N (%) | | WIF1 N (%) |
| | N | Hypo-M | Hyper-M | P value | Hypo-M | Hyper-M | P value |
| Differentiation degree | | 0.011 | 0.083 | 0.255 |
| Poor | 49 | 15 (27.3) | 34 (13.5) | 46 (17.4) | 3 (7.0) | 39 (17.4) | 10 (12.0) |
| Moderate or well | 258 | 40 (72.7) | 218 (86.5) | 218 (82.6) | 40 (93.0) | 185 (82.6) | 73 (88.0) |
| aHypomethylation | bHypermethylation |

| Table 3 The overall survival rates at 1, 3, 5 and 8 year in groups stratified by methylation in tumor tissues (N = 307) |
|---|
| Groups | 1 year | 3 year | 5 year | 8 year |
| | OSR (SE) | P value | OSR (SE) | P value | OSR (SE) | P value | OSR (SE) | P value |
| All patients (N = 307) | 0.915 (0.018) | 0.748 (0.027) | 0.646 (0.028) | 0.518 (0.039) |
| SFRP1 | | | | |
| Hypomethylation (N = 55) | 0.872 (0.052) | 0.660 (0.070) | 0.472 (0.071) | 0.258 (0.116) |
| Hypermethylation (N = 252) | 0.925 (0.019) | 0.767 (0.030) | 0.683 (0.031) | 0.562 (0.042) |
| SFRP2 | | | | |
| Hypomethylation (N = 246) | 0.905 (0.021) | 0.720 (0.031) | 0.603 (0.032) | 0.455 (0.048) |
| Hypermethylation (N = 43) | 0.976 (0.023) | 0.928 (0.040) | 0.904 (0.046) | 0.822 (0.062) |
| WIF1 | | | | |
| Hypomethylation (N = 224) | 0.932 (0.020) | 0.755 (0.032) | 0.627 (0.034) | 0.491 (0.046) |
| Hypermethylation (N = 83) | 0.868 (0.041) | 0.730 (0.055) | 0.700 (0.051) | 0.595 (0.073) |
| Co-methylation-2 | | | | |
| Co-methylation-2L b | 0.905 (0.020) | 0.720 (0.031) | 0.603 (0.032) | 0.462 (0.044) |
| Co-methylation-2H c | 0.976 (0.023) | 0.928 (0.040) | 0.904 (0.046) | 0.822 (0.062) |
| Co-methylation-3 | | | | |
| Co-methylation-3L d | 0.912 (0.019) | 0.735 (0.029) | 0.623 (0.030) | 0.493 (0.039) |
| Co-methylation-3H e | 0.957 (0.043) | 0.913 (0.059) | 0.913 (0.059) | 0.852 (0.080) |

*aOverall Survival Rate (Standard Error) 
*bCo-methylation-2 L: patients with promoter hypomethylation of at least one gene (SFRP1 or SFRP2)
*cCo-methylation-2H: patients with promoter hypermethylation of SFRP1 and SFRP2 
*dCo-methylation-3 L: patients with promoter hypomethylation of at least one gene (SFRP1 or SFRP2 or WIF1)
*eCo-methylation-3H: patients with promoter hypermethylation of SFRP1, SFRP2 and WIF1
Table 4 Univariate and multivariate Cox analysis for association between methylation and OS in 307 CRC patients

| Variables | Number | Patients (N=307) | Deaths (N=127) | Crude HR (95% CI) | P value | Adjusted HR \(^a\) (95% CI) | P value | Adjusted HR \(^b\) (95% CI) | P value |
|-----------|--------|-----------------|----------------|------------------|---------|---------------------------|---------|---------------------------|---------|
| SFRP1     |        |                 |                |                  |         |                           |         |                           |         |
| Hypomethylation | 55  | 31              | 1.00           | 1.00             | 0.001   | 0.970                     | 0.672   | 0.884                     | 0.280   |
| Hypermethylation | 252 | 96              | 0.505 (0.336–0.760) | 0.084           | 0.096   | 0.672 (0.437–1.032)       | 0.686 (0.447–1.051) | 0.688 (0.443–1.069) |
| SFRP2     |        |                 |                |                  |         |                           |         |                           |         |
| Hypomethylation | 264 | 119             | 1.00           | 1.00             | 0.001   | 0.005                     | 0.777   | 0.754                     | 0.034   |
| Hypermethylation | 43  | 8               | 0.307 (0.149–0.633) | 0.015           | 0.030   | 0.343 (0.164–0.718)       | 0.410 (0.200–0.842) | 0.455 (0.219–0.944) |
| WIF1      |        |                 |                |                  |         |                           |         |                           |         |
| Hypomethylation | 224 | 98              | 1.00           | 1.00             | 0.399   | 0.688                     | –       | –                         | –       |
| Hypermethylation | 83  | 29              | 0.836 (0.552–1.267) | –               |         | –                         | –       | –                         | –       |
| Co-methylation-2 c | |                 |                |                  |         |                           |         |                           |         |
| Co-methylation-2L | 264 | 119             | 1.00           | 1.00             | 0.001   | 0.003                     | 0.100   | 1.00                      | 0.013   |
| Co-methylation-2H d | 43  | 8               | 0.298 (0.145–0.612) | –               |         | 0.333 (0.159–0.694)       | 0.398 (0.192–0.821) | 0.442 (0.212–0.923) |
| Co-methylation-3 |        |                 |                |                  |         |                           |         |                           |         |
| Co-methylation-3L e | 284 | 123             | 1.00           | 1.00             | 0.018   | 0.032                     | 1.000   | 1.00                      | 0.155   |
| Co-methylation-3H f | 23  | 4               | 0.300 (0.110–0.814) | –               |         | 0.326 (0.117–0.908)       | 0.401 (0.146–1.106) | 0.479 (0.174–3.21) |

\(^a\)Controlling for the variables which included age, gender, CEA, CA19–9, TNM staging, pathological classification, differentiation degree and postoperative radiotherapy

\(^b\)Controlling for the variables which included age, gender, CEA, CA19–9, multiple polyps, tumor location, TNM staging, pathological classification, histologic classification, differentiation degree, postoperative chemotherapy and postoperative radiotherapy

\(c\)Co-methylation-2L: patients with promoter hypomethylation of at least one gene (SFRP1 or SFRP2)

\(d\)Co-methylation-2H: patients with promoter hypermethylation of SFRP1 and SFRP2

\(e\)Co-methylation-3L: patients with promoter hypomethylation of at least one gene (SFRP1 or SFRP2 or WIF1)

\(f\)Co-methylation-3H: patients with promoter hypermethylation of SFRP1, SFRP2 and WIF1
classification, differentiation degree and postoperative radiotherapy while the PS-2 model concentrated on PS-1 and the factors of multiple polyps, tumor location, histologic classification and postoperative chemotherapy. Our findings stem from objective analysis instead of external confounding factors.

Usually, as tumor-suppressor gene, SFRP1 and SFRP2 methylation were inversely correlated with the mRNA expression, and the expressions were increased after demethylation treatment in CRC cell lines [9]. Our results were contradicted with the above hypothesis that silencing of SFRP1 and SFRP2 by hypermethylation caused a better prognosis for the CRC patients. Furthermore, other researchers had the same conclusion as ours. Perez et al. found that RASSF2 hypermethylation was associated with a better prognosis of breast cancer [39]. Therefore, we believed that the gene methylation might lead to additional genetic changes or interact with other factors, rather than dependent on gene methylation alone.

![Fig. 2 Survival curve of CRC patients with SFRP2 hypermethylation and SFRP2 hypomethylation](image)

![Fig. 3 Survival curve of CRC patients with co-methylation-H2 and co-methylation-L2](image)
| Symbol  | Subgroup | Univariate Cox | Multivariate Cox | Propensity score-1 | Propensity score-2 |
|---------|----------|----------------|------------------|--------------------|--------------------|
|         |          | Crude HR (95%CI) | Adjusted HR (95%CI) | P value | Adjusted HR (95%CI) | P value | Adjusted HR (95%CI) | P value |
| SFRP2   | Age      |                |                  |         |                    |         |                    |         |
|         | < 45 years-old | 0.150 (0.020–1.148) | 0.021 (0.001–0.348) | 0.007 | 0.126 (0.016–1.025) | 0.053 | 0.161 (0.021–1.263) | 0.082 |
|         | ≥ 45 years-old | 0.346 (0.160–0.748) | 0.018 (0.019–0.911) | 0.028 | 0.479 (0.221–1.035) | 0.061 | 0.537 (0.246–1.173) | 0.119 |
|         | Gender    |                |                  |         |                    |         |                    |         |
|         | Male      | 0.373 (0.149–0.935) | 0.035 | 0.357 (0.135–0.945) | 0.038 | 0.471 (0.186–1.197) | 0.113 | 0.551 (0.213–1.427) | 0.219 |
|         | Female    | 0.214 (0.066–0.698) | 0.011 | 0.311 (0.091–1.056) | 0.061 | 0.328 (0.098–1.102) | 0.071 | 0.291 (0.085–1.005) | 0.051 |
|         | Tumor location |            |                  |         |                    |         |                    |         |
|         | Colon     | 0.177 (0.043–0.733) | 0.017 | 0.120 (0.027–0.527) | 0.005 | 0.203 (0.049–0.843) | 0.028 | 0.215 (0.052–0.899) | 0.035 |
|         | Rectum    | 0.413 (0.178–0.960) | 0.040 | 0.570 (0.237–1.366) | 0.207 | 0.673 (0.291–1.557) | 0.355 | 0.722 (0.308–1.695) | 0.455 |
|         | TNM Staging |            |                  |         |                    |         |                    |         |
|         | I–II      | 0.372 (0.132–1.048) | 0.061 | 0.375 (0.126–1.119) | 0.079 | 0.442 (0.156–1.254) | 0.125 | 0.428 (0.150–1.221) | 0.112 |
|         | III–IV    | 0.311 (0.113–0.859) | 0.024 | 0.280 (0.097–0.809) | 0.019 | 0.374 (0.133–1.048) | 0.061 | 0.452 (0.160–1.272) | 0.132 |
|         | Postoperative chemotherapy | | | | | | | |
|         | Yes       | 0.249 (0.078–0.797) | 0.019 | 0.284 (0.085–0.945) | 0.040 | 0.381 (0.117–1.239) | 0.109 | 0.365 (0.111–1.203) | 0.098 |
|         | No        | 0.360 (0.142–0.910) | 0.031 | 0.392 (0.150–1.026) | 0.056 | 0.448 (0.177–1.130) | 0.089 | 0.535 (0.207–1.384) | 0.197 |
| SFRP1+ SFRP2 | Age      |                |                  |         |                    |         |                    |         |
|         | < 45 years-old | 0.150 (0.020–1.148) | 0.068 | 0.021 (0.001–0.348) | 0.007 | 0.119 (0.014–1.025) | 0.053 | 0.151 (0.019–1.225) | 0.077 |
|         | ≥ 45 years-old | 0.334 (0.155–0.720) | 0.005 | 0.399 (0.181–0.879) | 0.023 | 0.463 (0.212–1.008) | 0.052 | 0.523 (0.238–1.152) | 0.108 |
|         | Gender    |                |                  |         |                    |         |                    |         |
|         | Male      | 0.356 (0.148–0.886) | 0.026 | 0.339 (0.130–0.884) | 0.027 | 0.448 (0.179–1.119) | 0.086 | 0.526 (0.206–1.343) | 0.179 |
|         | Female    | 0.214 (0.066–0.698) | 0.011 | 0.311 (0.091–1.056) | 0.061 | 0.328 (0.098–1.103) | 0.072 | 0.304 (0.090–1.022) | 0.054 |
|         | Tumor location |            |                  |         |                    |         |                    |         |
|         | Colon     | 0.177 (0.043–0.733) | 0.017 | 0.120 (0.027–0.527) | 0.005 | 0.200 (0.048–0.832) | 0.027 | 0.213 (0.051–0.890) | 0.034 |
|         | Rectum    | 0.397 (0.172–0.918) | 0.031 | 0.546 (0.227–1.312) | 0.176 | 0.666 (0.278–1.551) | 0.337 | 0.708 (0.297–1.690) | 0.437 |
|         | TNM Staging |            |                  |         |                    |         |                    |         |
|         | I–II      | 0.372 (0.132–1.048) | 0.061 | 0.375 (0.126–1.119) | 0.079 | 0.445 (0.157–1.260) | 0.127 | 0.434 (0.152–1.237) | 0.118 |
|         | III–IV    | 0.295 (0.108–0.809) | 0.018 | 0.263 (0.092–0.751) | 0.013 | 0.352 (0.127–0.970) | 0.044 | 0.419 (0.147–1.193) | 0.103 |
Table 5 Subgroup analysis on the association between methylation and OS (Continued)

| Symbol | Subgroup | Univariate Cox | Multivariate Cox | Propensity score-1 | Propensity score-2 |
|--------|----------|----------------|------------------|--------------------|--------------------|
|        |          | Crude HR (95%CI) | P value | Adjusted HR \(^{b}\) (95%CI) | P value | Adjusted HR \(^{c}\) (95%CI) | P value |
| Postoperative chemotherapy | No       | 0.249 (0.078–0.797) | 0.019 | 0.284 (0.085–0.945) | 0.040 | 0.381 (0.117–1.239) | 0.109 | 0.360 (0.109–1.191) | 0.094 |
|        | Yes      | 0.343 (0.137–0.861) | 0.023 | 0.372 (0.144–0.961) | 0.041 | 0.426 (0.168–1.076) | 0.071 | 0.517 (0.200–1.332) | 0.172 |

\(^a\)All HR values were referenced by hypomethylation
\(^b\)Controlling for the variables which included age, gender, CEA, CA19–9, TNM staging, pathological classification, differentiation degree and postoperative radiotherapy
\(^c\)Controlling for the variables which included age, gender, CEA, CA19–9, multiple polyps, tumor location, TNM staging, pathological classification, histologic classification, differentiation degree, postoperative chemotherapy and postoperative radiotherapy
Our subgroup analyses were stratified by age, gender, tumor location, TNM staging and postoperative chemotherapy. First, our result showed that patients with SFRP2 hypermethylation or co-hypermethylation of SFRP1 and SFRP2 had a lower risk of death in groups of ≥45 years old, male, colon cancer and TNM staging III-IV in traditional univariate and multivariate Cox. In addition, the patients with SFRP2 hypermethylation or co-hypermethylation of SFRP1 and SFRP2, who did not receive postoperative chemotherapy, had a lower risk of death while their HRs was consistent. So, we hypothesized that SFRP2 methylation played a more significant impact than SFRP1 on prognosis. The postoperative chemotherapy with co-hypermethylation of SFRP1 and SFRP2 was positively associated with patients’ prognosis, whereas SFRP2 methylation was negatively associated with patients’ prognosis. Therefore, we hypothesize that SFRP1 methylation and SFRP2 methylation synergistically affect patients’ outcomes. PS has been proved to be a useful, innovative and creative statistical method for evaluating intervention effects in non-experimental or observational studies. PS analysis confirmed the stability and reliability of the results of multivariate survival analysis. Through propensity score analysis, we found that co-hypermethylation of SFRP1 and SFRP2 could be more suitable for prognostic risk assessment of CRC than other predictors. Furthermore, the multiple combinations of genes with similar functions and structures could increase the clinical evaluation value of methylation. Secondly, it is well known that CRC patients with TNM staging III-IV have a poor prognosis. Nevertheless, we found that subgroups of promoter hypermethylation of SFRP2 or co-hypermethylation of SFRP1 and SFRP2 had a better prognosis than those of hypomethylation among patients with TNM staging III-IV. The findings triggered us to put them onto the clinical practice and precisely assess the individualized treatment of CRC patients.

With the aid of similar statistical analysis, we deeply explored the relationship between the methylation of all cg sites of the three genes and the prognosis in the TCGA database (Additional file 7: Table S6). There were no statistically significant association between the methylation of cg04255616 probe (SFRP1) and cg25185173 probe (SFRP2) and prognosis of CRC patients while the WIF1 methylation was significantly associated with CRC prognosis. Unlike the Caucasian and African America as the primary research objects of the TCGA database, all participants in our research were Chinese. In addition, two probes in the TCGA database were located in the promoter region of SFRP1 and SFRP2. The amplicons with multiple CpG sites in the promoter regions contained precise representativeness. Similarly, we applied the average methylation values of all probes in the TCGA as the WIF1 methylation level for prognostic analysis. The number of cg sites (probes) in the TCGA is much more than that in the target amplicon of our study, as might cause different results. Interestingly, Chen et al. found that hypermethylation of NDRG4 promoter was a predictor of poor overall survival in gastric cancer in China. However, the opposite results were observed in the TCGA cohort. They also believed that racial differences of study population caused different outcomes [40].

Up to now, this is a novel study about the methylation of Wnt signaling pathway related to genes on the prognosis of postoperative CRC patients. By MS-HRM, we had examined tumor tissues and adjacent non-tumor tissues obtained from surgical patients. Compared to other forms of clinical samples, tissue samples containing a large number of cells were used for the detection of gene methylation. However, some limitations should also be considered. Firstly, our study did not involve the assessment of tumor-specific death. Secondly, due to limited collected information about the treatment of CRC patients, the analyses of the associations between methylation of SFRP1, SFRP2, and WIF1 and treatment decision were restricted to some extent, which might be used to establish more personalized treatment strategies.

Conclusions
The promoter of SFRP1, SFRP2, and WIF1 were frequently hypermethylated in CRC tumor tissues. Promoter hypermethylation of SFRP2, co-hypermethylation of SFRP1 and SFRP2, and co-hypermethylation of SFRP1, SFRP2, and WIF1 could be considered as independent prognostic predictors for the survival advantage in patients with CRC. For colon cancer, patients with promoter hypermethylation of SFRP1 or co-hypermethylation of SFRP1 and SFRP2 had higher overall survival. In TNM staging III-IV, patients with co-hypermethylation of SFRP1 and SFRP2 had a favorable prognosis.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12985-019-6436-0.
Additional file 7: Table S6. Univariate and multivariate Cox analysis for association of cg methylation of SFRP1, SFRP2, and WIF1 with OS in TCGA.

Abbreviations
AUC: Area under curve; CI: Confidence intervals; CRC: Colorectal cancer; HR: Hazard ratio; MS-HRM: Methylation-sensitive high resolution melting; OS: Overall survival; PS: Propensity score; ROC: Receiver operator characteristic; SFRP1: Secreted frizzled-related protein 1; SFRP2: Secreted frizzled-related protein 2; SFRPs: Secreted frizzled-related proteins; TCGA: The Cancer Genome Atlas; WIF1: Wnt inhibitory factor 1

Acknowledgements
We want to thank Dr. Justina Ucheojor Onwuka for the linguistic assistance during the revising of the manuscript.

Authors’ contributions
XL and YZ carried out the concept and design. AQ, TX, YL, and HS completed the collection and management of the data. XL, JF, HB, and DL performed data verification, sample processing and data analysis and interpretation. XL, JF, and YZ worked to complete the writing. All authors read and approved the final manuscript.

Funding
This study was funded by the National Natural Science Foundation of China grants (Grant numbers 81473055 and 30972539). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Harbin Medical University. All participants were provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 5 June 2019 Accepted: 5 December 2019
Published online: 12 December 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424.
2. Arnold M, Serra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
3. Brenner H, Kloer M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.
4. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.
5. Lopez-Seira L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer. 2008;98(12):1881–5.
6. Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015;149(5):1204–1225.e1212.
7. Bili MP, Foester A, Luigi A, Zlobec I. Characterization of CDRN2Ag16 (methylated) and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med. 2012;10:173.
8. Ongino S, Nozho K, Kirchner GJ, Kasai T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumor LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100(23):1734–8.
9. Hu H, Wang T, Pan R, Yang Y, Li B, Zhou C, Zhao J, Huang Y, Duan S. Hypomethylated promoters of secreted frizzled-related protein genes are associated with colorectal cancer. PLoS Pathology oncology research; 2018.
10. Fang Y, Wang L, Zhang Y, Ge C, Xu C. WIF-1 methylation and beta-catenin expression in colorectal serosal metastasis. Zhonghua bing li xue za zhi. 2014;49(1):5–9.
11. Silva AL, Dawson SN, Arends MJ, Guttula K, Hall N, Cameron EA, Huang TH, Brenton JD, Tavare S, Biez M, et al. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer. 2014;14:891.
12. Chen YZ, Liu D, Zhao YX, Wang HT, Gao Y, Chen Y. Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis. Tumour Biol. 2014;35(9):6001–10.
13. Sui C, Wang G, Chen Q, Ma J. Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer. Tumour Biol. 2014;35(10):10457–65.
14. Hu H, Li B, Zhou C, Ying X, Chen M, Huang T, Chen Y, Ji H, Pan R, Wang T, et al. Diagnostic value of WIF1 methylation for colorectal cancer: a meta-analysis. Oncotarget. 2018;9(4):5378–86.
15. Galamb O, Kalmar A, Peterfia B, Csalaj I, Bodor D, Ribili D, Krenacs T, Patai AV, Wichmann B, Bartak BK, et al. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Epigenetics. 2016;11(8):588–602.
16. Suzuki H, Gabrielsson E, Chen W, Anbazhagan R, van Engeland M, Weijsenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone desacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31(2):141–9.
17. Patai AV, Valcz G, Hollosi P, Kalmar A, Peterfia B, Patai A, Wichmann B, Sipsik S, Bartak BK, Leizter K, et al. Comprehensive DNA methylation analysis reveals a common ten-gene methylation signature in colorectal adenomas and carcinomas. PLoS One. 2015;10(8):e0133836.
18. Rawson JB, Manco M, Mikoticj M, Daltcy D, Dicks E, Buchanan DD, Youngusband HB, Parfrey PS, Young JP, Pollett A, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 2011;32(5):741–7.
19. Kumar A, Gospatale SB, Pandey A, Singh P. Prognostic relevance of SFRP1 gene promoter methylation in colorectal carcinoma. Asian Pac J Cancer Prev. 2019;20(5):1571–7.
20. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted-frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 2011;34(2):E88–95.
21. Samaei NM, Yazdani Y, Alizadeh-Navaei R, Azadeh H, Farzamandfar T. Promoter methylation analysis of WNT/beta-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer. J Biomed Sci. 2014;21:73.
22. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (M- HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35(6):e41.
23. Kalmar A, Peterfia B, Hollosi P, Kalmar A, Patai A, Scholler A, Krenacs T, Tulassay Z, Mohar B. Bisulfite-based DNA methylation analysis from recent and archived formalin-fixed, paraffin embedded colorectal tissue samples. Pathol Oncol Res. 2015;21(4):1149–56.
24. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.
25. Li Y, Xing C, Wei M, Wu H, Hu X, Li S, Sun G, Zhang G, Wu B, Zhang F, et al. Combining red blood cell distribution width (RDW-CV) and CEA predict poor prognosis for survival outcomes in colorectal Cancer. J Cancer. 2019;10(5):162–70.
26. Agul O, Ceritkaya E, Yalaza M, Oden S, Tez M. Prognostic efficacy of inflammation-based markers in patients with curative colorectal cancer resection. World J Gastrointest Oncol. 2017;9(7):300–7.
27. Alper M, Cukur S, Belenli O, Suna M. Evaluation of the immunohistochemical stain patterns of survivin, Bak and Bag-1 in colorectal cancers and comparison with polyps situated in the colon. Hepato-gastroenterology. 2008;55(85):1169–73.
28. Teiljar S, Stintzing S, Giardello F, Tabernero J, Van Cutsem E, Beer F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA oncology. 2016;3(2):194–201.
29. Tawadros PS, Paquette IM, Hanly AM, Mellgren AF, Rothenberger DA, Madoff RD. Adenocarcinoma of the rectum in patients under age 40 is increasing: impact of signet-ring cell histology. Dis Colon Rectum. 2015; 58(5):474–8.

30. Du F, Shi SS, Sun YK, Wang JW, Chi Y. Clinicopathological characteristics and prognosis of colorectal cancer in Chinese adolescent patients. Chin Med J. 2015;128(23):3149–52.

31. Liu Y, Wang Y, Hu F, Sun H, Zhang Z, Wang X, Luo X, Zhu L, Huang R, Li Y, et al. Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China. Oncotarget. 2017;8(37):61239–52.

32. Shao SX, Liao XL, Zhang YK, Qiu JM, Zhang XF, Yang GG. Multi-gene methylation detection increases positive methylation rate in colorectal cancer. Zhonghua wei chang wai ke za zhi. 2012;15(6):629–32.

33. Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006;12(44):7113–7.

34. Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, Sturzl M, Hohenberger W, Matzel KE. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum. 2007;50(10):1618–26 discussion 1626-1617.

35. Galamb O, Kalmar A, Bartak BK, Patai AV, Leiszter K, Peterfia B, Wichmann B, Valcz G, Veres G, Tulassay Z, et al. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma. World J Gastroenterol. 2016;22(47):10325–40.

36. Bartak BK, Kalmar A, Peterfia B, Patai AV, Galamb O, Valcz G, Spisak S, Wichmann B, Nagy ZB, Toth K, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics. 2017;12(9):751–63.

37. Park SK, Song CS, Yang HJ, Jung YS, Choi KY, Koo DH, Kim KE, Jeong KU, Kim HO, Kim H, et al. Field Cancerization in sporadic Colon Cancer. Gut iver. 2016;10(5):773–80.

38. PRRDB R. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.

39. Perez-Janices N, Blanco-Luquin I, Torrea N, Liechtenstein T, Escors D, Cordoba A, Vicente-Garcia F, Jauregui I, De La Cruz S, Illarramendi JJ, et al. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. Oncotarget. 2015;6(27):23944–58.

40. Chen X, Yang Y, Liu J, Li B, Xu Y, Li C, Xu Q, Liu G, Chen Y, Ying J, et al. NDRG4 hypermethylation is a potential biomarker for diagnosis and prognosis of gastric cancer in Chinese population. Oncotarget. 2017;8(5):8105–19.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.